Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?

Leppert, Wojciech

doi:10.4172/2161-0479.1000e113

J Autacoids

2012

DOI: 10.4172/2161-0479.1000e113

|View full text |Cite

Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?

Wojciech Leppert¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 18 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone

2014

View full text Add to dashboard Cite

In patients managed with opioids for chronic pain, opioid-induced bowel dysfunction—specifically, opioid-induced constipation (OIC)—is a common side effect, which has a significant impact on quality of life (QoL). The most recent developments for management of OIC are opioid antagonists, including naloxone, a competitive antagonist of peripheral opioid receptors that reverses opioid-induced peripheral gastrointestinal (GI) effects. A prolonged-release formulation of naloxone is available in combination with oxycodone (OXN PR). To review the specific role of OXN PR in the management of chronic pain and OIC and its impact on QoL and healthcare costs, a review of available relevant literature was conducted. Healthcare costs can be up to ten times higher for patients with GI events than for those without. Assessment of QoL in patients with OIC is essential, and multiple tools for its evaluation are available. The Bowel Function Index (BFI), a tool that was specifically developed and validated to measure bowel function in patients with OIC, can be an indication of QoL. In patients with moderate-to-severe chronic pain, randomized trials have demonstrated that OXN PR has equal analgesic efficacy and safety, but results in improved bowel function, compared with prolonged-release oxycodone (Oxy PR) alone. In conclusion, randomized studies using the BFI, as well as real-world clinical practice observations, have demonstrated improved QoL for patients taking OXN PR. This combination should allow more patients to benefit from the analgesic efficacy of opioid therapy and should minimize the side effects of constipation that correspond to improvements in QoL and healthcare offsets.

show abstract

Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone

2014

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?

Cited by 1 publication

References 18 publications

Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone

Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone

Contact Info

Product

Resources

About